Replies to post #96079 on Elite Pharmaceuticals Inc (ELTP)

[3454]

"Unfortunately, uplisting does not necessarily mean the end to manipulation," yeah check out the story on overstock .com

[BuddyGuise]

Agree, new eyes don't want to read about the bogey man, then want dd. Here's some:

"Tons of Billions of Dollars" where we're heading.

((((ELITES FORMULATIONS WERE SUPERIOR)))) results of first trial.

Second trial:

almost no exposure levels to naltrexone

HUGE!!!

"As I have stated before, we have set in motion several initiatives that will have significant impact on Elite's future," commented Nasrat Hakim, Elite's President and CEO. "Following the success of the pilot bioequivalence study in December for ELI-201, we are delighted with the results of this pivotal bioequivalence clinical study for ELI-200, our second opioid abuse deterrent product. ELI-200 is expected to be filed this year and will be the first NDA product filed by Elite with the U.S. Food and Drug Administration."

15 ADT products in pipeline!!!

SIX quarters averaging quarterly revenue gains of 93%.

Compare Q2'13 vs Q2'12 Revenue increased +131%
Compare Q3'13 vs Q3'12 Revenue increased +30%
Compare Q4'13 vs Q4'12 Revenue increased +134%
Compare Q1'14 vs Q1'13 Revenue increased +27%
Compare Q2'14 vs Q2'13 Revenue increased +83%
Compare Q3'14 vs Q3'13 Revenue increased +154%

"Our goal is to create a strong commercial foundation to support Elite's development into a leader in the abuse resistant opioid market, and we have clearly demonstrated great strides toward this goal during the quarter," commented Nasrat Hakim, President and CEO of Elite. "We initiated human clinical trials of the first of our ART products, achieved the first milestones and revenues from the 12 ANDA's acquired in August, and our commercial generic products continue to perform well."